Regulated information

Third quarter revenues: €132 million

2021 first half results

2021 Half year results

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

Q1 2021 sales

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

Vetoquinol wins the Animal Pharm’s award for best European company 2020

February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm.

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.”

Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia

January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health.

Vétoquinol markets CEFTIOCYL® and KEFLORIL® two new injectable antibiotics for livestock

Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is
launching Ceftiocyl® and Kefloril®, two new injectable antibiotics for livestock.
The products are being brought to market by the Group and its subsidiaries in
both domestic and export markets.

Vétoquinol appoints RÉGIS VIMAL DU MONTEIL Group Finance and Legal Director

November 30, 2010 (Lure, France) – Vétoquinol has appointed Régis Vimal du Monteil as
Group Legal and Financial Director.

Vétoquinol registers its injectable Marbocyl® 2% and Marbocyl® 10% antibiotics in Japan

November 18, 2010 (Lure, France) – Vétoquinol has just obtained Marketing
Authorisation (MA) from Japanese drug authorities for its Marbocyl® 2% and
Marbocyl® 10% antibiotics for livestock, through collaboration with Meiji Seika
Kaisha, Ltd.

Strong Sales in the 3rd Quarter of 2010

Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments.

Mise à disposition ou de consultation du rapport financier semestriel 2010 (french)

Le Rapport financier semestriel 2010 de Vétoquinol peut être consulté ou téléchargé sur
le site Internet de la société : www.vetoquinol.com, rubrique « Investisseurs & Journalistes ».

Strong Results in the first half of 2010

The Board of Directors of Vétoquinol, meeting on August 30, reviewed the group’s business and approved its interim 2010 financial statements.

Continued Sales Growth in the second Quarter of 2010

Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth.

BOREVE-D: Vétoquinol is participating in a project to raise awareness of the need to treat pain in cattle

June 30, 2010 (Lure, France) – Vétoquinol, in collaboration with two other veterinary laboratories, is participating in a project organised by the Syndicat de l’Industrie du Médicament Vétérinaire (SIMV) to raise awareness of the need to treat pain in cattle.

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2009 (french version)

The registration document of Vétoquinol relative to fiscal year 2009, including the annual financial report relative to fiscal year 2009, was registered with the Autorité des marchés financiers (“the AMF”) on April 22th, 2010.

Continued sales growth driven by sustained organic growth

April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.

Departure of Pierre Konareff

April 14, 2010 (Lure, France) – The Vétoquinol Group today announces the departure of Pierre
Konareff, Group Director of Finance and Legal Affairs, because of differences concerning his
position in the Group. Pierre Konareff joined Vétoquinol in July 2008.

2009 annual earnings

March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements.

Redemption of tranche A bonds

February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds.

Strong growth in 2009 Revenues: +7.6%

January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions.

VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States

January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success.